Compare ACADIA Pharmaceuticals Inc. (ACAD) vs GoPro Inc (GPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs GoPro Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while GoPro Inc trades at $0.79 (market cap $121.79M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 36.9× GoPro Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | GPRO | |
|---|---|---|
Market Cap | $4.49B | $121.79M |
Sector | Health | Technology |
52-Week High | $28.06 | $2.88 |
52-Week Low | $20.06 | $0.64 |
Enterprise Value | $3.69B | $169.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
GoPro (GPRO) trades at $0.701, down 3.96% for the day, reflecting persistent financial distress. The stock shows a bearish technical outlook with negative cash flows and consecutive earnings misses. Recent news highlights a strategic review for potential sale or merger, announced on May 11, 2026, following weak Q1 2026 results. Revenue has declined from $1.1B in 2022 to $652M in 2025, with net losses deepening, indicating significant operational challenges.
The investment outlook remains highly speculative. The strategic sale process offers a potential catalyst, but substantial risks include ongoing cash burn, negative equity, and competitive pressures. Analyst sentiment is mixed with a cautious hold bias. Investors should weigh the binary outcome of a successful strategic transaction against the company's fundamental deterioration and explicit going-concern risks noted in recent disclosures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
